Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NORDITROPIN

« Back to Dashboard
Norditropin is a drug marketed by Novo Nordisk Inc and is included in two NDAs. It is available from two suppliers. There are twelve patents protecting this drug.

This drug has forty-three patent family members in twenty-seven countries.

The generic ingredient in NORDITROPIN is somatropin recombinant. There are two drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the somatropin recombinant profile page.

Summary for Tradename: NORDITROPIN

Patents:12
Applicants:1
NDAs:2
Suppliers: see list2

Pharmacology for Tradename: NORDITROPIN

Clinical Trials for: NORDITROPIN

American Norditropin Studies - Registry of Growth Hormone (GH) Patients
Status: Suspended Condition: Growth Hormone Deficiency

Observational Prospective Study on Patients Treated With Norditropin®
Status: Enrolling by invitation Condition: Growth Hormone Disorder; Growth Hormone Deficiency in Children; Adult Growth Hormone Deficiency; Genetic Disorder; Turner Syndrome; Foetal Growth Problem; Small for Gestational Age; Chronic Kidney Disease; Chronic Renal Insufficiency; Noonan Syndrome

Diurnal Variation of Exogenous Peptides (GH Puls/Jurgita I)
Status: Completed Condition: Growth Hormone Deficiency

Growth Hormone Use in Albright Hereditary Osteodystrophy
Status: Recruiting Condition: Pseudohypoparathyroidism Type 1a; Albright Hereditary Osteodystrophy

Saizen® Solution for Injection Adult Growth Hormone Deficiency (GHD) Immunogenicity Study
Status: Terminated Condition: Growth Hormone Deficiency (GHD)

A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency
Status: Completed Condition: Growth Hormone Disorder; Adult Growth Hormone Deficiency

An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)
Status: Recruiting Condition: Adult Growth Hormone Deficiency

Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents
Status: Completed Condition: Growth Hormone Disorder; Growth Hormone Deficiency in Children; Foetal Growth Problem; Small for Gestational Age; Genetic Disorder; Turner Syndrome; Chronic Kidney Disease; Chronic Renal Insufficiency; Delivery Systems

Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device
Status: Completed Condition: Turner's Syndrome; Human Growth Hormone Deficiency

Effects of Short-term Growth Hormone in HIV-infected Patients
Status: Completed Condition: HIV Lipodystrophy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc
NORDITROPIN FLEXPRO
somatropin recombinant
INJECTABLE;INJECTION021148-010Mar 1, 2010RXNo5,849,700<disabled><disabled>
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-004Oct 1, 2004DISCNNo6,235,004<disabled>Y<disabled>
Novo Nordisk Inc
NORDITROPIN
somatropin recombinant
INJECTABLE;INJECTION021148-003Jun 20, 2000DISCNNo5,849,700<disabled><disabled>
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-006Oct 1, 2004DISCNNo6,004,297<disabled>Y<disabled>
Novo Nordisk Inc
NORDITROPIN NORDIFLEX
somatropin recombinant
INJECTABLE;INJECTION021148-005Oct 1, 2004DISCNNo5,849,700<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: NORDITROPIN

Country Document Number Publication Date
Canada2125855Jul 08, 1993
Netherlands300126Jul 01, 2003
Russian Federation94045932Apr 20, 1997
JapanH11315031Nov 16, 1999
Portugal618807Mar 31, 2003
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc